July 21, 2023Open Access

Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

These findings suggest that concomitant use of PPIs with palbociclib may hinder the complete therapeutic benefits of palbociclib in patients with breast cancer.

Mark Helpful

Bookmark

Relay

View Full Paper

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Lee et al. (Fri,) studied this question.

synapsesocial.com/papers/69dce903a6f240e91f1334de https://doi.org/https://doi.org/10.1001/jamanetworkopen.2023.24852

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?2012 · 331 citations
2Comparative effectiveness of early-line <em>nab</em>-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis2018 · 34 citations
3The Impact of Proton Pump Inhibitors on the Human Gastrointestinal Microbiome2014 · 198 citations
4Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future2020 · 467 citations
5Landmark analysis: A primer2019 · 215 citations